Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders

Summary One hundred and twenty-four sera, from patients with various leukemic B-cell chronic lymphoproliferative diseases were investigated at diagnosis by ELISA for their soluble CD23 content. Immunophenotyping was carried out in all patients, and in a selected subset the mean number of membrane-bound CD23 molecules per cell was also investigated. Seventy-three patients had typical B chronic lymphocytic leukenia, 41 leukemic B-cell disorders with atypical morphological and/or immunophenotypic features, 5 had low-grade follicular cell lymphoma in the leukemic phase, and 5 had splenic lymphoma with villous lymphocytes Soluble CD23 levels were significantly higher than in normal sera (mean±SD: typical B chronic lymphocytic leukemia 3,650±4,654 U/ml, atypical B chronic lymphocytic leukemia 3,440±4,671 U/ml, follicular cell lymphoma 3,200±1,511 U/ml, splenic lymphoma with villous lymphocytes 8,236±7,294 U/ml, controls 137±128 U/ml;P<0.001). More advanced Rai's stages were related to higher soluble CD23 levels (P<0.01), both in typical and atypical B chronic lymphocytic leukemias, the highest levels and the best correlation with the absolute number of circulating CD19+ cells (r=0.50) being observed in the typical form. The number of membrane-bound CD23 molecules per cell was significantly higher in typical than in atypical B chronic lymphocytic leukemias (mean number 156,727±94,668 vs. 12,010±10,643,P<0.001). Our data suggest that soluble CD23 levels correlate with the clinical and biological features of leukemic B-cell lymphoproliferative disorders.     

Diminished expression of CD19 in B-cell lymphomas

BACKGROUND: CD19 is expressed on most B-cell lymphomas; however, the frequency and types of B-cell lymphomas with low-level expression of CD19 are not well characterized. METHODS: We reviewed flow cytometric histograms specifically for decreased CD19 expression on 349 cases analyzed by the Flow Cytometry Laboratory at University Hospitals of Cleveland (Cleveland, Ohio). Results of flow cytometry were correlated with the morphologic diagnosis. RESULTS: Of the cases reviewed, 125 (36%) showed a visible decrease in CD19 expression compared with normal B lymphocytes. Decreased CD19 expression was noted in 79% of follicular lymphomas (27 of 34), 36% of small lymphocytic lymphomas/chronic lymphocytic leukemias (82 of 228), 31% of mantle cell lymphomas (4 of 13), 24% of diffuse large B-cell lymphomas (8 of 33), and 13% of marginal zone B-cell lymphomas/lymphoplasmacytoid lymphomas (4 of 30) and was not observed in any Burkitt lymphoma (0 of 5) or hairy cell leukemia (0 of 6). Decreased CD19 expression was significantly more frequent in follicular lymphomas than in other lymphoma subtypes (P < 0.001). No significant difference was observed in the frequency of decreased CD19 expression based on histologic grade of follicular lymphoma. CONCLUSIONS: Diminished expression of CD19 expression occurs frequently in B-cell lymphomas, in particular follicular lymphoma, and may be helpful in identifying B-cell lymphoma cells in complex cell mixtures such as bone marrow specimens.     

慢性淋巴细胞系统白血病免疫表型分析

目的：研究国内慢性淋巴细胞系统折血病的免疫表型特点。方法：采用单参数和多参数流式细胞术分析了163例慢性淋巴细胞系统白血病的免疫表型。结果：71.8％（117/163）患者共表达CD5和B细胞标志。采用WHO引用的计分系统，将病例分为B-慢性淋巴细胞白血病（B-CLL），毛细胞白血病（HCL）和其他B淋巴细胞增殖性疾病。典型的B-CLL表达CD5、CD23、CD20、CD19、HLA-DR，但仍有部分患者表达CD22、CD11c、CD25和FMC7。CD103似为HCL最特异的标志。但仅仅依靠免疫表型难以鉴别非典型B-CLL、B细胞-幼淋巴细胞白血病（B-PLL）和外套细胞淋巴瘤（MCL），细胞遗传学或分子生物学检查将有助于鉴别诊断。以同一标本中残存的正常淋巴细胞为内参照，计算前向角光散射（FSC）指数和抗原表达指数，可定量地表示细胞的大小和抗原表达的强度，使不同的标本具有可比性。结论：免疫表型分析是诊断慢性淋巴细胞系统白血病非常有用的依据。     

Combined isolation of CD34+ progenitor cells and reduction of B cells from peripheral blood by use of immunomagnetic methods

BACKGROUND: Malignant cells may contribute to relapse after autologous hematopoietic cell transplantation The effectiveness of a double immunomagnetic purging strategy combining CD34-positive with B-negative cell selection to purge peripheral blood progenitor cells (PBPCs) from patients with chronic lymphoproliferative disorders has been analyzed. STUDY DESIGN AND METHODS: Twenty-two CD34+ cell selections from patients with follicular lymphoma (n = 14), chronic lymphocytic leukemia (n = 6), mantle cell lymphoma (n = 1), and splenic marginal zone lymphoma (n = 1) were performed by use of a magnetic cell selector followed by a negative cell selection step with anti-CD19 monoclonal antibody bound to immunomagnetic beads. RESULTS: The PBPC components contained median CD34+ cells of 1.24 percent (range, 0.38-3.92%) and CD19+ cells of 1.83 percent (range, 0.06-69.7%). After positive selection (n = 22), 49 percent (range, 16-72%) of CD34+ cells were recovered with a purity of 93 percent (range, 24-99%). The double-positive and -negative selections (n = 20) yielded 57.5 percent of CD34+ cells (range, 33.4-79.4%) with a purity of 95 percent (range, 63-99%). Logarithms of B-cell reduction in the CD34+-cell-enriched B-cell-depleted component had a median value of 3.63 (range, 2.74-4.84 log) and CD19+ and CD5+ cells for chronic lymphocytic leukemia patients with more than 4.56 log (>3.6-5.6 log). Of 13 PBPC components that had a tumor-specific clonal signal, 10 became PCR negative after the double-selection procedure. CONCLUSION: Combined positive and negative magnetic cell selection achieves a high grade of tumor cell reduction with up to 77 percent of the grafts being negative for tumor-specific clonal signal by PCR analysis. This technique preserves an adequate recovery of progenitor cells able to engraft.     

Absolute CD4 and CD8 counts and CD4-to-CD8 ratios in eight patients with indolent B-cell chronic lymphocytic leukemia

BACKGROUND: There are some patients with B-cell chronic lymphocytic leukemia who exhibit an extraordinary natural resistance to this malignancy, which lasts for many years. In this study, we report the T-cell subset values and ratios in eight such patients. METHODS: Impath (New York, NY) evaluated immunophenotyping by performing flow cytometry. Absolute CD4 and CD8 counts and CD4:CD8 ratios were performed at Memphis Pathology Laboratory, Memphis, Tennessee. RESULTS: CD4 and CD8 counts and CD4:CD8 ratios were normal in all eight patients, in contrast to the suppressor cell proliferation and low helper-suppressor ratios that have been previously reported in other patients with B-cell chronic lymphocytic leukemia. CONCLUSION: These results require further study to determine their significance. Implications for further study are discussed.     

Molecular and flow cytometry characterization during the follow-up of three simultaneous lymphoproliferative disorders: hairy cell leukemia, monoclonal B-cell lymphocytosis, and CD4(++) /CD8(+/- dim) T-large granular lymphocytosis--a case report

The simultaneous diagnosis of hairy cell leukemia and monoclonal B-cell lymphocytosis with the characteristics of "indolent" chronic lymphocytic leukemia is rare but not unknown. However, an association with a third clonal lymphoproliferative disorder has not previously been described. We report the simultaneous presence of hairy cell leukemia, monoclonal B-cell lymphocytosis, and alpha beta CD4(++) /CD8(+) T-cell large granular lymphocytosis in a 63-year-old man. After the diagnosis, the three lymphoproliferative disorders (i.e., two of B-cell lineage and one of T-cell lineage) were characterized by analysis of multiple sequential bone marrow and peripheral blood samples using flow cytometry and molecular techniques. We discuss these findings in the context of chronic antigen stimulation, immunosuppression, and apoptotic pathway alterations, which might be implicated in the accumulation of these abnormal clones in the same patient. Because the phenotype of the three clones is compatible with fully differentiated B lymphocytes (consistent with a postgerminal origin) and T-CD4(++) cells, we favor the possibility of an antigen-driven mechanism and a dysregulation of homeostatic apoptosis in this patient.     

恶性血液病细胞中tankyrase表达与端粒酶活性关系研究

为研究以白血病为主的恶性血液病细胞中端粒酶活性正向调控基因tankyrase的表达与端粒酶活性的关系并初步探讨tankyrase对端粒酶活性调控的机理和意义 ,以实时定量RT PCR技术对髓细胞系白血病细胞株K5 6 2 ,HL 6 0 ,U937,NB4 ,THP 1,HEL ,Dami,T淋巴细胞性白血病细胞株 6T CEM ,Jurkat和B细胞淋巴瘤细胞株Raji中tankyrase的表达进行检测 ,同时检测端粒酶逆转录酶hTERT的表达确定端粒酶活性 ,并以经磁珠分离的正常人CD3 ,CD19 和CD33 细胞和 10份正常人骨髓单个核细胞做对照。结果发现 :tankyrase在恶性血液病细胞株中的表达明显高于正常对照 (U =19,P <0 .0 1) ,其中髓系白血病细胞株中的表达高于正常人CD33 细胞 ,T淋巴细胞性白血病细胞株和B细胞淋巴瘤细胞株中的表达分别高于正常人CD3 和CD19 细胞。髓系恶性血液病细胞株tankyrase的表达 (0 .0 0 32± 0 .0 0 10 )明显低于淋系恶性血液病细胞株的表达 (0 .0 12± 0 .0 0 16 ) (F =2 3,P <0 .0 1)。Tankyrase与hTERT的表达呈正相关 (相关系数为 0 .395 ,P <0 .0 5 )。结论 :tankyrase在恶性血液病细胞株中呈高表达 ,与端粒酶活性呈正相关 ,提示tankyrase可能是恶性血液病中端粒酶活性增高的原因之一。     

Phenotypic classification of malignant lymphoma

The phenotypic characters of the lymphoma cell are important in the diagnosis of this disease. We recently tested whether the flow cytometry with fresh biopsy sample might be useful in the diagnosis of the lymphoma. In our date, 1. a rise and fall of the surface immunoglobulin kappa/lambda ratio indicated the monoclonal proliferation of the B-cell, 2. the increased proportion of the CD5/CD23 double positive cells indicated B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma, 3. the decreased proportion of the CD2 positive cells and the increased proportion of the CD19 positive cells indicated B-cell lymphoma. These findings suggest that the flow cytometry is of adjunctive importance in making a diagnosis of the lymphoma.     

类风湿关节炎患者外周血CD23^＋／CD19^＋细胞表达状况的研究

目的研究外周血CD19^＋及CD23^＋／CD19^＋细胞的表达在类风湿关节炎（RA）发病机制和病情进展中的意义。方法RA组和正常对照组各20例,应用流式细胞术检测外周血中CD19^＋及CD23^＋／CD19^＋细胞的表达率,比较两组的差异,并分析其与血沉（ESR）、C反应蛋白（CRP）的相关性。结果RA组外周血CD19^＋及CD23^＋／CD19^＋细胞表达率均高于对照组,（10．236±2．212）％vs（6．870±1．052）％,（5．134±1．069）％vs（2．100±0．652）％（P〈0．05或〈0．01）。CD23^＋／CD19^＋细胞的表达率与实验室指标ESR、CRP均呈正相关（P〈0．01）,CD19^＋细胞表达率与ESR、CRP无明显相关关系（P〉0．05）。结论RA患者外周血存在CD19^＋及CD23^＋／CD19^＋细胞的表达增高,检测CD23^＋／CD19^＋细胞的表达情况可能对RA病情监控具有一定的应用价值。     

CD23 antigen regulation and signaling in chronic lymphocytic leukemia.

B lymphocytes from patients with chronic lymphocytic leukemia (B-CLLs), strongly express the CD23 antigen, a surface marker with significant prognostic importance in this disease. Because we previously reported that IL-4 shows a poor capacity for CD23 expression on B-CLLs, we first examined the possible mechanisms underlying CD23 overexpression on B-CLLs and found that mitogen-activated CLL T cells release soluble factors that are capable, in synergy with IL-4, of strongly inducing CD23. Using neutralizing Abs, we noticed that the T-cell-derived enhancing activity is entirely ascribed to the combined effects of IFN gamma (potent inhibitor of CD23 on normal B cells), TNF alpha (which has no effect on normal B cells), and IL-2 (which has a slight enhancing effect on both CLL and normal B cells). Furthermore, recombinant IFN gamma as well as IFN alpha, TNF alpha, and IL-2 (but not IL-3, IL-5, IL-6, IL-7, and lymphotoxin) significantly enhance CD23 protein and mRNA expression on B-CLLs, in the presence or absence of IL-4. Inasmuch as optimal CD23 expression absolutely requires the combination of IFN gamma, IL-2, TNF alpha (the production of which is increased in CLL disease), and IL-4, it was relevant to show that IL-4 mRNA is indeed expressed in fresh T-CLL cells. We next examined the possible role of CD23 in the regulation of B-CLL proliferation. Signaling through CD23 via ligation of the antigen by F(ab')2 anti-CD23 MAb but not Fab fragments inhibits the cytokine-induced B-CLL DNA synthesis. It is concluded that the CD23 gene is abnormally regulated in B-CLL disease and that cross-linking of CD23 molecule delivers a negative growth signal to the leukemic B cells.     

miR-9-3在慢性淋巴细胞白血病中的功能与调控机制

目的 探讨microRNA-9-3(miR-9-3)在慢性淋巴细胞白血病中的作用及调控机制。方法 采用甲基化特异性聚合酶链反应(MSP)技术检测8例正常人骨髓组织和外周血、78例新确诊慢性淋巴细胞性白血病患者骨髓组织和7种白血病细胞系的甲基化水平; 采用Western blot技术检测甲基化阳性白血病细胞株的NF-κB1信号转导通路活化水平。结果 正常对照组miR-9-3启动子呈非甲基化状态; 7种白血病细胞株中只有I83-E95和WAC3CD5+两种细胞株种呈非甲基化状态(MSP阳性率为28.6%); 78例慢性淋巴细胞性白血病患者中65例发生miR-9-3甲基化(MSP阳性率为83%)。去甲基化药物5-氮杂-2'-脱氧胞苷(5-Aza2'Dc)处理后的I83-E95和WAC3CD5+细胞株miR-9-3均处于去甲基化状态。结论 慢性淋巴细胞性白血病患者存在miR-9-3异常甲基化,可能导致癌细胞异常增生; miR-9-3去甲基化可抑制NF-κB1信号通路活化,表明miR-9-3可能可以通过该通路抑制癌细胞凋亡,引发患者疾病恶化; 甲基化的白血病细胞株可被去甲基化药物抑制,因此miR-9-3可以作为治疗慢性淋巴细胞白血病的新基因靶点。     

Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia

CD5-expressing B lymphocytes from patients with selected chronic lymphoproliferative disorders were used to determine whether monoclonal populations of CD5+ human B cells produce autoantibodies. CD5+ B cells from 19 patients with chronic lymphocytic leukemia (CLL) and one with diffuse well-differentiated lymphocytic lymphoma (DWDL) were cultured, with and without mitogenic stimulation, to obtain Ig from these cells. 17 of the 20 samples produced Ig in vitro. mAb from nine of the 17 patients were reactive with either IgG, ssDNA, or dsDNA. In every instance, the autoantibodies displayed monotypic L chain usage that correlated precisely with the L chain expressed on the CD5+ leukemic B cell surface. These monoclonal autoantibodies varied in their degree of antigenic specificity; some were quite specific, reacting with only one antigen, whereas others were polyspecific, reacting with two or all three autoantigens tested. Three features distinguish these autoantibodies from those observed in prior studies of CD5+ B cells. First, they are clearly the products of monoclonal populations of CD5+ cells; second, several react with dsDNA, a specificity not previously reported and often seen in association with significant autoimmune disorders; and third, two of the monoclonal autoantibodies secreted by the CD5+ clones were of the IgG class. Although not all of the Ig-producing, CD5-expressing clones elaborated mAbs reactive with the autoantigens tested, greater than 50% did. It is possible that with a broader autoantigenic panel or with larger quantities of CLL/DWDL-derived Ig, even more autoantibody-producing clones might be identified. These studies may have important implications for the antigenic specificity of subsets of human B lymphocytes as well as for lymphoproliferative and autoimmune disorders in general.     

Clinical significance of monoclonal B cells in cerebrospinal fluid

BACKGROUND: Morphologically malignant lymphocytes in the cerebrospinal fluid (CSF) are highly suggestive of central nervous system involvement by lymphoid malignancy. Although flow cytometry is increasingly used to detect a monoclonal B-cell population in the CSF, the significance of this finding in the absence of morphologically identifiable malignant cells is unknown. METHODS: We reviewed CSF flow cytometric results in 32 patients studied at a single institution over 5 years and identified patients who had monoclonal B-cells in the CSF. Clinical presentation and course were reviewed. RESULTS: Twelve patients had a monoclonal B-cell population in the CSF, but only three had clinical evidence of malignant CNS disease. Of the other nine patients, 4 had nonmalignant neurologic disease and five had a lymphoproliferative disorder: chronic lymphocytic leukemia (n = 4) and mantle cell lymphoma (n = 1). In patients who had chronic lymphocytic leukemia and mantle cell lymphoma, the monoclonal B-cell population was small and had an immunophenotype identical to that of circulating malignant B cells. None of these nine patients developed clinical evidence of malignant CNS involvement during follow-up. CONCLUSION: In patients who have indolent B-cell malignancies, the presence of monoclonal B cells in the CSF may not be diagnostic of clinically significant CNS involvement by a lymphoid malignancy.     

CD117在白血病细胞上的表达分析

目的　探讨细胞表面分化抗原CD117在各型白血病细胞上的表达规律及其意义。方法　采用CD4 5/SSC双参数散点图设门方法进行三色流式细胞术细胞表面分化抗原分析。结果　急性髓系白血病 (AML)患者CD117表达率为 6 8%,慢性粒细胞白血病急变期 (CML BC)患者CD117表达率为 80 %,而在急性淋巴细胞白血病中表达率极低 ,仅为 2 %。在慢性淋巴细胞白血病、CML慢性期中阴性。在AML中CD117主要表达在M0 /M1( 72 %)、M2 ( 88%)、M4 ( 5 0 %)、M5a( 75 %)、M6( 10 0 %) ,但在M3 和M5b中表达率较低 (分别为 39%和 2 9%) ,在M3 中CD117的表达率高于CD34 及HLA DR。CD117与CD14 在AML中的表达呈负相关。结论　CD117有助于淋巴系与髓系白血病的鉴别 ,并有助于白血病克隆与正常细胞的区分。     

The FcɛR2/CD23 antigen: A hallmark of chronic lymphocytic leukemia B cells

Summary The effect of different stimuli on the expression of the low-affinity receptor for the Fc fragment of IgE (FcɛR2/CD23) on peripheral blood B cells from patients with chronic lymphocytic leukemia (CLL) was investigated. CLL B cells cultured for 3 days in medium alone showed a progressive decrease of the FcɛR2/CD23 expression, while the addition to the cell cultures of IgE or interleukin-4 had a slackening effect on the decrease of the FcɛR2/CD23. In contrast, in the presence of interferon-γ the proportion of FcɛR2/CD23⁺ cells was more rapidly reduced compared to CLL B cells cultured in medium alone. Stimulation of CLL B cells withStaphylococcus aureus Cowan I (SAC) bacteria, which are able to enhance the expression of FcɛR2/CD23 on normal B cells, induced a rapid loss of the FcɛR2/CD23 from CLL B cells.     

从再生障碍性贫血患者检出阵发性睡眠性血红蛋白尿症异常细胞的观察

目的：探讨在再生障碍性贫血（再障）患者中检出阵发性睡眠性血红蛋白尿症（ＰＮＨ）异常细胞的发生率。方法：用荧光标记的抗ＣＤ５９抗体，以流式细胞仪检测缺失ＣＤ５９的异常细胞。结果：１０名正常人骨髓单个核细胞及外周血红细胞和中性粒细胞的ＣＤ５９标记率均＞９５％。２３例再障患者中约２／３标记率正常，另外１／３患者的标记率有不同程度的减低。结论：该法是从再障患者检出少量ＰＮＨ异常细胞的良好手段，可用以早期发现再障－阵发性睡眠性血红蛋白尿症综合征。     

CDll7在白血病细胞上的表达分析

目的 探讨细胞表面分化抗原CD117在各型白血病细胞上的表达规律及其意义。方法 采用CD45／SSC双参数散点图设门方法进行三色流式细胞术细胞表面分化抗原分析。结果急性髓系白血病(AML)患CD117表达率为68％，慢性粒细胞白血病急变期(CML-BC)患CD117表达率为80％，而在急性淋巴细胞白血病中表达率极低，仅为2％。在慢性淋巴细胞白血病、CML慢性期中阴性。在AML中CD117主要表达在M0／M1(72％)、M2(88％)、M4(50％)、M5b(75％)、M6(100％)，但在M3和M5b中表达率较低(分别为39％和29％)，在从中CD1l7的表达率高于CD54及HLA—DR。CD117与CD14在AML中的表达呈负相关。结论 CD117有助于淋巴系与髓系白血病的鉴别，并有助于白血病克隆与正常细胞的区分。     

CD123在淋巴细胞白血病细胞中的表达及在微量残留病监测中的作用

目的 探讨CD123在淋巴细胞白血病中的表达特点及意义.方法 应用多参数流式细胞术检测139例淋巴细胞白血病患者CD123的表达.以10名正常人骨髓淋巴细胞作对照.对105例急性B淋巴细胞白血病(B-ALL)患者行细胞遗传学分析.对97例B-ALL患者进行白血病微量残留病(MRD)分析.结果 ①10名正常人骨髓中B淋巴干/祖细胞、成熟B淋巴细胞及T淋巴细胞均不表达CD123.139例淋巴细胞白血病患者中,5例T-ALL和23例慢性B淋巴细胞白血病(B-CLL)患者CD123均阴性.111例B-ALL患者中106例CD123阳性(阳性率95.49%),其中包括12例早期前B-ALL、57例普通B-ALL、37例前B-ALL;5例成熟B-ALL患者CD123阴性.②在B-ALL患者中,CD123表达水平与p-Akt表达水平呈正相关,超二倍体患者组CD123表达水平高于非超二倍体患者组.③MRD阳性与阴性组患者比较,12个月内复发率分别为63.04%和21.56%,差异有统计学意义(P<0.01).MRD阴性组无病生存率[(48.23±1.82)%]高于MRD阳性组[(36.06±2.62)%].CD123在复发B-ALL患者中表达稳定性高.结论 CD123在B-ALL患者中普遍中度至强度表达,复发时表达稳定性高,是MRD分析较好的标志之一.     

Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia

B-cell chronic lymphocytic leukemia (B-CLL) is a well-defined clinical entity with heterogeneous molecular and cytogenetic features. Here, we analyze the impact of trisomy 12, del(13q), del(17p), and del(11q) as determined by interphase fluorescence in situ hybridization analysis of purified neoplastic B-CLL cells on their immunophenotype, DNA ploidy status and proliferative rate.Overall, 111 of 180 (62%) B-CLL cases studied displayed one (50%) or more (12%) genetic abnormalities, del(13q) (35%) being more frequently detected than trisomy 12 (23%) followed by del(11q) (9%) and del(17p) (8%). Trisomy 12 was associated with a higher frequency of DNA aneuploidy, stronger expression of CD19, CD20, CD22, CD24, CD27, CD79b, CD38, and sIg and lower reactivity for CD43 with respect to cytogenetically nonaltered cases. In turn, cases with del(13q) displayed greater reactivity for CD20, FMC7, CD27, CD22, CD5, and bcl2, while del(11q) was associated with brighter expression of CD38, FMC7, CD25, and sIg. Hierarchical clustering analysis of the immunophenotype of B-CLL cases with cytogenetic abnormalities allowed the identification of three different groups of patients with increasing frequencies of trisomy 12, del(11q), and del(13q). Remarkably, none of the cytogenetic abnormalities analyzed except coexistence of 13q- and 17p- had a clear impact on the proliferative index of B-CLL cells.     

B淋巴瘤CD23表达研究

目的 研究Ｂ淋巴瘤ＣＤ２３表达及临床意义。方法 用ＳＰ原位免疫组化方法检测ＣＤ２３表达。结果 ２０例Ｂ淋巴瘤中有１８例ＣＤ２３表达，且与恶性程度及生存时间相关。结论 结果支持Ｂ淋巴ＣＤ２３高表达的假设；ＣＤ２３在Ｂ淋巴瘤发生中起作用和该淋巴因子可能对治疗（药理学调节）有重要意义。